**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

An approximately 23-year-old woman developed psychiatric adverse events during treatment with chloroquine for antimalarial chemoprophylaxis.

The woman nurse presented at the age of 25 years due to anxiousness. She was diagnosed with COVID-19, and then was treated accordingly. After she finished the quarantine period, she expressed her wish to work with a health NGO. The NGO suggested to complete a course of hydroxychloroquine. At that time, it was revealed that, two years before this presentation, when she was travelled Haiti, she took chloroquine 300mg tablet \[*frequency not stated*\], scheduled to be taken for 4 weeks, for antimalarial chemoprophylaxis. No adverse event occurred in Haiti. However, 48 hours after she returned, she exhibited behavioural problems with agitation, and was hospitalised. A subsequent mental exam showed that she was conscious with temporal disorientation, but without neurological deficit. She also exhibited tachypsychia, incoherent speech with delusional syndrome, logorrhoea with echolalia, insomnia and psychomotor agitation. Her urine drug screen was negative. Additionally, the reports of thick smear microscopy, EEG, CT-scan and ECG also resulted negative and there was no evidence of biological inflammatory syndrome. The chloroquine level was found to be 0.5 mg/L. Based on the clinical presentation and investigational results, chloroquine-related psychiatric adverse events was diagnosed \[*duration of treatment to reaction onset not stated*\].

The woman\'s therapy with chloroquine was therefore discontinued, and she was treated with olanzapine. After 8 days of hospital stay, she showed improvement.
